T1	PROC 46 163	Estudio Fase III, prospectivo, multicéntrico, randomizado, doble ciego, controlado con placebo, de 2 grupos paralelos
T2	PROC 170 202	comparar la eficacia y seguridad
T3	PROC 207 218	tratamiento
#1	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	PROC 268 275	placebo
#2	AnnotatorNotes T4	C0032042; Placebos; Therapeutic or Preventive Procedure
T5	DISO 293 315	asma persistente grave
#3	AnnotatorNotes T5	C1960048; Severe persistent asthma; Disease or Syndrome
T6	CHEM 328 339	corticoides
#4	AnnotatorNotes T6	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T7	CHEM 223 232	masitinib
T8	DISO 371 375	asma
#5	AnnotatorNotes T8	C0004096; Asthma; Disease or Syndrome
T9	PROC 316 323	tratado
#6	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	Date 13 17	2010
T11	Dose 247 254	6 mg/kg
T12	Frequency 254 258	/día
T13	LIVB 279 288	pacientes
#7	AnnotatorNotes T13	C0030705; Patients; Patient or Disabled Group
T14	Route 340 346	orales
#8	AnnotatorNotes T14	C1527415; Oral Route of Drug administration; Functional Concept
#9	AnnotatorNotes T1	C0282461; Phase 3 Clinical Trials; Research Activity + C0033522; Prospective Studies; Research Activity + C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product + C2826345; Parallel Study; Research Activity
#10	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity
#11	AnnotatorNotes T7	C2351398; masitinib; Organic Chemical · Pharmacologic Substance 
R1	Used_for Arg1:T7 Arg2:T3	
R2	Has_Dose_or_Strength Arg1:T7 Arg2:T11	
R3	Has_Frequency Arg1:T7 Arg2:T12	
R4	Experiences Arg1:T13 Arg2:T3	
R5	Experiences Arg1:T13 Arg2:T4	
R6	Experiences Arg1:T13 Arg2:T5	
R7	Experiences Arg1:T13 Arg2:T9	
R8	Used_for Arg1:T6 Arg2:T9	
R9	Has_Route_or_Mode Arg1:T6 Arg2:T14	
R10	Overlap Arg1:T4 Arg2:T9	
R11	Overlap Arg1:T3 Arg2:T9	
A1	Experiencer T13 Patient
